Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

INAB

IN8bio Inc

Dec 10 • 04:00PM ET

0.3050

Dollar change 0.0000
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA GILD ADAP CLLS FATE BLUE EDIT IBRX TCRT

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.75	Insider Own	31.52%	Shs Outstand	72.48M	Perf Week	-4.45%
Market Cap	22.11M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.00%	Shs Float	49.63M	Perf Month	-11.23%
Income	-31.88M	PEG	-	EPS next Q	-0.07	Inst Own	21.95%	Short Float	1.73%	Perf Quarter	0.79%
Sales	0.00M	P/S	-	EPS this Y	43.67%	Inst Trans	13.01%	Short Ratio	0.73	Perf Half Y	-78.21%
Book/sh	0.18	P/B	1.66	EPS next Y	51.18%	ROA	-151.16%	Short Interest	0.86M	Perf Year	-69.19%
Cash/sh	0.06	P/C	5.53	EPS next 5Y	-	ROE	-241.97%	52W Range	0.22 - 2.48	Perf YTD	-77.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-50.62%	ROI	-258.49%	52W High	-87.70%	Beta	-0.00
Dividend TTM	-	Quick Ratio	1.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	40.55%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.84	EPS Y/Y TTM	32.96%	Oper. Margin	-	RSI (14)	47.74	Volatility	10.94% 11.76%
Employees	31	Debt/Eq	0.64	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	4.10
Option/Short	No / Yes	LT Debt/Eq	0.44	EPS Q/Q	34.14%	Payout	-	Rel Volume	0.00	Prev Close	0.31
Sales Surprise	-	EPS Surprise	11.76%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	1.18M	Price	0.31
SMA20	-4.67%	SMA50	1.76%	SMA200	-58.99%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Initiated	Laidlaw	Buy	$7.50
Aug-30-22	Initiated	H.C. Wainwright	Buy	$14

Dec-10-24 07:00AM	IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting (GlobeNewswire) -9.25%
Dec-02-24 07:00AM	IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference (GlobeNewswire) +20.77%
Nov-25-24 07:00AM	IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-12-24 04:26PM	IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.39% -9.49%
07:00AM	IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
09:00AM	Loading…
Nov-05-24 09:00AM	IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +21.10%
Oct-01-24 08:00AM	IN8bio Announces Pricing of $12.4 Million Private Placement (GlobeNewswire)
Sep-05-24 08:33AM	IN8bio cuts staff and pipeline to focus on AML cell therapy (Pharmaceutical Technology) -27.33%
Sep-04-24 04:01PM	IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia (GlobeNewswire) -7.02%
Aug-29-24 06:05AM	IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 08:05AM	IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 (GlobeNewswire) -9.13%
Aug-08-24 04:05PM	IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jun-24-24 08:00AM	IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire)
Jun-14-24 02:04PM	IN8bio Decline After Favorable Leukemia Results Could Be Profit-Taking (Barrons.com) -35.12%
Jun-13-24 04:01PM	IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 (GlobeNewswire) +14.29%
06:05AM	Loading…
Jun-03-24 06:05AM	IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.40%
May-24-24 08:00AM	IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 (GlobeNewswire)
May-23-24 05:00PM	IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting (GlobeNewswire)
May-14-24 10:00AM	IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress (GlobeNewswire)
May-13-24 08:00AM	IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 (GlobeNewswire)
May-09-24 10:57PM	INAB Stock Earnings: IN8bio Misses EPS for Q1 2024 (InvestorPlace)
04:00PM	IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-30-24 06:05AM	IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire)
Apr-24-24 08:00AM	IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 04:05PM	IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Apr-09-24 04:30PM	IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 (GlobeNewswire)
Mar-14-24 09:54PM	INAB Stock Earnings: IN8bio Misses EPS for Q4 2023 (InvestorPlace) -7.20%
04:00PM	IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 (GlobeNewswire) -7.26%
Feb-26-24 08:00AM	IN8bio to Present at Upcoming Investor Conferences (Business Wire)
08:00AM	Loading…
Feb-14-24 08:00AM	IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology (GlobeNewswire) -6.67%
Jan-04-24 08:00AM	IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals (GlobeNewswire) +12.10%
Dec-11-23 04:05PM	IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia (GlobeNewswire) +29.29% +27.73%
09:00AM	IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement (GlobeNewswire)
Dec-07-23 08:00AM	IN8bio Appoints Dr. Corinne Epperly to Board of Directors (GlobeNewswire) -5.08%
Dec-05-23 08:00AM	IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia (GlobeNewswire)
Nov-20-23 07:00AM	IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma (GlobeNewswire)
Nov-10-23 07:00AM	IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.61%
Nov-06-23 08:00AM	IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-02-23 09:17AM	IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-23 08:00AM	IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-12-23 08:00AM	IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire) -5.00%
Sep-29-23 08:00AM	IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.31%
Sep-26-23 08:00AM	IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City (GlobeNewswire)
Sep-20-23 08:00AM	IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +12.62%
Sep-19-23 08:03AM	IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents (GlobeNewswire) +7.80%
Sep-06-23 08:00AM	IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-15-23 08:00AM	IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire)
Aug-10-23 04:15PM	IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-23 08:00AM	IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility (GlobeNewswire)
Jun-05-23 08:00AM	IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting (GlobeNewswire) -13.33%
May-17-23 08:00AM	IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer (GlobeNewswire)
May-12-23 08:00AM	IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.80%
May-02-23 05:08PM	IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting (GlobeNewswire) +21.84% +11.32%
May-01-23 08:00AM	IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors (GlobeNewswire) +19.18%
Apr-26-23 10:00AM	IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma (GlobeNewswire) -36.33%
Apr-24-23 08:00AM	IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023 (GlobeNewswire) +185.71%
Apr-17-23 09:00AM	IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023 (GlobeNewswire) +6.61%
Apr-11-23 08:00AM	IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting (GlobeNewswire) +10.66%
Mar-30-23 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.11%
Mar-16-23 08:00AM	IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023 (GlobeNewswire) -7.52%
Mar-01-23 08:00AM	IN8bio to Present at the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) +5.88%
Feb-23-23 07:00AM	IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue (GlobeNewswire) -9.44%
Feb-21-23 07:00AM	IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-17-23 07:00AM	IN8bio to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference (GlobeNewswire)
Jan-05-23 07:00AM	IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals (GlobeNewswire)
Jan-03-23 07:00AM	IN8bio to Present at Biotech Showcase 2023 in San Francisco (GlobeNewswire)
Dec-12-22 07:00AM	IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100 (GlobeNewswire)
Dec-08-22 07:00AM	IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma (GlobeNewswire) -5.26%
Nov-10-22 07:30AM	IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire) +6.38%
Nov-03-22 09:10AM	IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-01-22 07:30AM	IN8bio to Present at November Investor Conferences (GlobeNewswire)
Sep-27-22 07:30AM	IN8bio to Present at Cantor Oncology & HemOnc Conference (GlobeNewswire)
Sep-15-22 07:30AM	IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400 (GlobeNewswire)
Sep-13-22 07:30AM	IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.98%
Sep-08-22 07:30AM	IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board (GlobeNewswire) +6.58%
Aug-30-22 04:15PM	IN8bio to Present at September Investor and Scientific Conferences (GlobeNewswire) +39.39% -6.16%
Aug-19-22 09:20AM	IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering (GlobeNewswire)
Aug-16-22 04:15PM	IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +6.17%
Aug-12-22 04:15PM	IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.57%
Aug-11-22 10:05PM	IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -10.00%
Jul-27-22 07:00AM	IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients (GlobeNewswire) +9.10%
Jul-21-22 07:00AM	Newly Issued European Patent Broadens IN8bios Drug Resistant Immunotherapy (DRI) Platform (GlobeNewswire)
Jul-12-22 08:00AM	IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development (GlobeNewswire) -5.28%
Jul-10-22 09:12AM	Is IN8bio (NASDAQ:INAB) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-30-22 04:15PM	IN8bio to Present at July Investor and Scientific Conferences (GlobeNewswire) -6.22%
Jun-08-22 08:00AM	IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences (GlobeNewswire)
Jun-06-22 07:00AM	IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022 (GlobeNewswire)
May-17-22 07:00AM	IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell Off-the-Shelf Induced Pluripotent Stem Cell Platform (GlobeNewswire) -11.43%
May-12-22 08:00AM	IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-22 08:00AM	IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting (GlobeNewswire)
May-04-22 08:00AM	IN8bio to Present at May Investor and Scientific Conferences (GlobeNewswire) +8.80%
May-03-22 11:00AM	Bullish IN8bio, Inc. (NASDAQ:INAB) investors are yet to receive a pay off on their US$1.0m bet (Simply Wall St.) +11.11%
Apr-13-22 08:30AM	IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments (GlobeNewswire)
Apr-05-22 04:15PM	IN8bio to Present at April Investor and Scientific Conferences (GlobeNewswire) +9.35%
Mar-28-22 08:00AM	IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant (GlobeNewswire)
Mar-17-22 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +9.42%

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INAB

IN8bio Inc

Upgrade your FINVIZ experience